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Critical-size defects in bones do not heal spontaneously and usually require the use of grafts. 
Unfortunately, grafts have several limitations. To improve bone formation, many clinicians now use bone 
morphogenetic proteins (BMP), particularly in spinal fusion, fracture healing, and in critical-size defect 
regeneration. However, multiple side effects of BMP treatment have been uncovered including increased 
incidence of cancer. Thus, there is great interest in alternatives that allow for safe and effective bone 
regeneration. Here we show the ability of thrombopoietin (TPO), the main megakaryocyte growth factor, 
to heal critical-size femoral defects rodents. 5mm or 4mm segmental defects were created in the femur of 
Long Evans rats or C57BL/6 mice, respectively. The defects were filled with a novel bioabsorbable 
scaffold which was loaded with recombinant human TPO, BMP-2, or saline, and held stable by a 
retrograde 1.6 mm intramedullary Kirschner wire (rats) or 23G needle (mice). Xrays were taken every 3 
weeks in rats and weekly in mice. Animal were sacrificed at 15 weeks, at which time micro-computed 
tomography (µCT) and histological analyses were performed. The results observed in mice and rats were 
similar. The saline control group did not show bridging callus at any time. Both the BMP-2 and TPO 
groups healed the defect, although bridging callus was evident at earlier times in the BMP-2 groups. 
However, the TPO groups showed a much more remodeled and physiologic contour on both Xray and 
µCT.  µCT and histological analysis confirms that compared to BMP-2, TPO-treated specimens have a 
thicker cortex but smaller diameter and smoother contour. TPO appears to restore the original bone 
contour by stimulating osteoblastogenesis, allowing for periosteal bridging and stabilization to occur, 
while simultaneously stimulating osteoclast formation. Thus, TPO may serve as a novel bone healing 
agent.  
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